These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Clinical experience with thalidomide and lenalidomide in multiple myeloma. Moehler T Curr Cancer Drug Targets; 2012 May; 12(4):372-90. PubMed ID: 22229246 [TBL] [Abstract][Full Text] [Related]
3. Immunomodulatory drugs as a therapy for multiple myeloma. De Raeve H; Vanderkerken K Curr Pharm Biotechnol; 2006 Dec; 7(6):415-21. PubMed ID: 17168657 [TBL] [Abstract][Full Text] [Related]
4. A systematic review of phase II trials of thalidomide/dexamethasone combination therapy in patients with relapsed or refractory multiple myeloma. von Lilienfeld-Toal M; Hahn-Ast C; Furkert K; Hoffmann F; Naumann R; Bargou R; Cook G; Glasmacher A Eur J Haematol; 2008 Oct; 81(4):247-52. PubMed ID: 18637031 [TBL] [Abstract][Full Text] [Related]
5. Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a phase II trial. Dingli D; Rajkumar SV; Nowakowski GS; Gertz MA; Dispenzieri A; Lacy MQ; Hayman S; Fonseca R; Lust JA; Kyle RA; Greipp PR; Witzig TE Haematologica; 2005 Dec; 90(12):1650-4. PubMed ID: 16330438 [TBL] [Abstract][Full Text] [Related]
6. Lenalidomide in the treatment of multiple myeloma. Rao KV Am J Health Syst Pharm; 2007 Sep; 64(17):1799-807. PubMed ID: 17724360 [TBL] [Abstract][Full Text] [Related]
7. United Kingdom myeloma forum position statement on the use of lenalidomide in multiple myeloma. Davies F; Morris C; Bird J; Cook G; Williams C; Tighe J; Cavenagh J; Behrens J; Schey S; Morgan G; Int J Lab Hematol; 2009 Apr; 31(2):119-31. PubMed ID: 19016917 [TBL] [Abstract][Full Text] [Related]
8. Current treatment strategies with lenalidomide in multiple myeloma and future perspectives. Larocca A; Cavallo F; Mina R; Boccadoro M; Palumbo A Future Oncol; 2012 Oct; 8(10):1223-38. PubMed ID: 23130924 [TBL] [Abstract][Full Text] [Related]
9. Thalidomide as salvage therapy for VAD-refractory multiple myeloma prior to autologous PBSCT. Ahmad I; Islam T; Chanan-Khan A; Hahn T; Wentling D; Becker JL; McCarthy PL; Alam AR Bone Marrow Transplant; 2002 Apr; 29(7):577-80. PubMed ID: 11979306 [TBL] [Abstract][Full Text] [Related]
10. Efficacy of low-dose thalidomide and dexamethasone as first salvage regimen in multiple myeloma. Palumbo A; Bertola A; Falco P; Rosato R; Cavallo F; Giaccone L; Bringhen S; Musto P; Pregno P; Caravita T; Ciccone G; Boccadoro M Hematol J; 2004; 5(4):318-24. PubMed ID: 15297848 [TBL] [Abstract][Full Text] [Related]
11. Lenalidomide in the treatment of multiple myeloma: a review. Armoiry X; Aulagner G; Facon T J Clin Pharm Ther; 2008 Jun; 33(3):219-26. PubMed ID: 18452408 [TBL] [Abstract][Full Text] [Related]
12. Thalidomide-dexamethasone as up-front therapy for patients with newly diagnosed multiple myeloma: thrombophilic alterations, thrombotic complications, and thromboprophylaxis with low-dose warfarin. Cini M; Zamagni E; Valdré L; Palareti G; Patriarca F; Tacchetti P; Legnani C; Catalano L; Masini L; Tosi P; Gozzetti A; Cavo M Eur J Haematol; 2010 Jun; 84(6):484-92. PubMed ID: 20192986 [TBL] [Abstract][Full Text] [Related]
13. Production of proangiogenic cytokines during thalidomide treatment of multiple myeloma. Dmoszyńska A; Bojarska-Junak A; Domański D; Roliński J; Hus M; Soroka-Wojtaszko M Leuk Lymphoma; 2002 Feb; 43(2):401-6. PubMed ID: 11999576 [TBL] [Abstract][Full Text] [Related]
14. Thalidomide for the treatment of multiple myeloma. Hattori Y; Iguchi T Congenit Anom (Kyoto); 2004 Sep; 44(3):125-36. PubMed ID: 15327481 [TBL] [Abstract][Full Text] [Related]
15. Management of the relapsed/refractory myeloma patient: strategies incorporating lenalidomide. Richardson P Semin Hematol; 2005 Oct; 42(4 Suppl 4):S9-15. PubMed ID: 16344100 [TBL] [Abstract][Full Text] [Related]
16. The efficacy and safety of pomalidomide in relapsed/refractory multiple myeloma in a "real-world" study: Polish Myeloma Group experience. Charlinski G; Grzasko N; Jurczyszyn A; Janczarski M; Szeremet A; Waszczuk-Gajda A; Bernatowicz P; Swiderska A; Guzicka-Kazimierczak R; Lech-Maranda E; Szczepaniak A; Wichary R; Dmoszynska A Eur J Haematol; 2018 Sep; 101(3):354-361. PubMed ID: 29882602 [TBL] [Abstract][Full Text] [Related]
17. Lenalidomide and its role in the management of multiple myeloma. Falco P; Cavallo F; Larocca A; Liberati AM; Musto P; Boccadoro M; Palumbo A Expert Rev Anticancer Ther; 2008 Jun; 8(6):865-74. PubMed ID: 18533796 [TBL] [Abstract][Full Text] [Related]
18. The influence of thalidomide therapy on cytokine secretion, immunophenotype, BCL-2 expression and microvessel density in patients with resistant or relapsed multiple myeloma. Dmoszynska A; Podhorecka M; Manko J; Bojarska-Junak A; Rolinski J; Skomra D Neoplasma; 2005; 52(2):175-81. PubMed ID: 15800717 [TBL] [Abstract][Full Text] [Related]